La vendita allo scoperto per Trump Media & Tech Gr dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Trump Media & Tech Gr. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Trump Media & Tech Gr (NASDAQ:DJTWW) Azioni, Report sulle vendite allo scoperto

Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $81 price target.

News

Price Target

Reiteration

Analyst Ratings

CRSP

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $81 Price Target

RiverNorth Marketplace Lending Corporation Common Stock

RiverNorth Capital and Income Fund Announces Preliminary Results of Oversubscribed Rights Offering, Expects $15.9M Gross Proceeds From 1.1M New Shares at $14.39 Each

ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency (AVP-D). The company has been issued a patent for ET-600's formulation that extends to 2044 and has an additional patent application under review by the United States Patent and Trademark Office. AVP-D is estimated to impact approximately 3,000 pediatric patients in the United States.

Health Care

General

ETON

The FDA Has Accepted Eton Pharmaceuticals' New Drug Application For ET-600, A Proprietary, Patented Formulation Of Desmopressin Oral Solution, For Review And Assigned A Prescription Drug User Fee Act Target Action Date Of February 25, 2026

Pump.fun may be one of the most polarizing platforms in crypto, but its financials are <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">hard to ignore</a>.
In a valuation breakdown, 10x Research concludes that the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based memecoin launchpad&#8217;s rumored $4 billion valuation, leaked via a now-deleted token sale <a href="https://x.com/cryptolyxe/status/1942311062256377929?s=46&amp;t=MuRujqZUAz3TQE1vmr3c6A">page</a> on Gate.io, still appears "relatively cheap" given its 2025 revenue performance.
According to the report, Pump.fun has generated $398 million in revenue year-to-date, far surpassing on-chain rival Raydium (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RAY</a>), which earned $52 million during the same period despite facilitating more than 10 times the trading volume. 
This revenue lead stems from Pump.fun's flat 1% fee on all bonding-curve token trades, giving it a high-margin model that few platforms in the space can match.
Applying Raydium's current revenue multiple of 11.5x to Pump.fun's annualized $796 million revenue implies a potential valuation of $9.1 billion. 
The $4 billion figure, based on the planned sale of 150 billion PUMP tokens at $0.004 each, translates to a multiple closer to 5x, which 10x frames as a bear-case valuation. 
"A $4 billion valuation appears relatively inexpensive," the report states, calling the pricing "conservative" given comparative market dynamics.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46259970/why-nano-labs-wants-to-control-a-big-chunk-of-binance-coins-circulating-supply">Why Nano Labs Wants To Control A Big Chunk Of Binance Coin&#8217;s Circulating Supply</a>
The report comes after Gate.io briefly published, then removed, a pre-sale page showing a public token offering scheduled for July 12. 
The sale would have raised $600 million from the release of 150 billion tokens, representing 15% of the total 1 trillion supply. 
The page described it as Pump.fun's "first official public token sale," but its removal has fueled speculation and confusion. 
A support message from Gate.io <a href="https://x.com/support_gateio/status/1942369211432722670">mentioned </a>"negotiations" between the exchange and the project, and confirmed that there is "no confirmed date or announcement for its reopening."
Despite volatility and reputational baggage surrounding memecoins, 10x points to Pump.fun's sticky user base, 729,000 weekly users and stable monthly revenues of $25–$30 million, as signals of resilience. 
Even with a 66% revenue drop from January to May and declining daily token launches, the platform continues to outperform Raydium in revenue by nearly 8x.
Importantly, the platform's move to launch its own AMM, PumpSwap, has allowed it to capture full fee revenue and further reduce reliance on Raydium, with whom it once had a mutually beneficial migration agreement. 
That relationship soured earlier this year, culminating in Raydium launching its own memecoin incubator, LaunchLab, just two days before PumpSwap went live.
While critics have noted that 98% of tokens launched on Pump.fun either fail or exhibit fraudulent behavior and that over 1,700 wallets lost more than $100,000 the revenue engine powering the protocol remains intact. 
Of the 4.26 million wallets active on the platform, more than half ended up with minor losses, while only 311 netted over $1 million in profit.
Still, 10x suggests that market skepticism tied to Pump.fun's memecoin-centric identity could be masking its underlying value. 
"If the $4–$12 billion valuation range materializes," the report says, "early positioning could provide asymmetric upside."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46259948/bitcoin-etfs-just-pulled-in-600-million-in-a-day-is-a-major-price-breakout-coming-next">Bitcoin ETFs Just Pulled In $600 Million In A Day—Is A Major Price Breakout Coming Next?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$RAY

$SOL

Why You Should Keep An Eye On Solana Project Pump.fun's $4B Price Tag

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $108 price target.

MMSI

Needham Reiterates Buy on Merit Medical Systems, Maintains $108 Price Target

AMPG

Castellum's New Subsidiary Inks Reseller Agreement With AmpliTech To Bring Low Noise Amplifiers And RF Components To Government Clients

Merck To Present New HIV Prevention and Treatment Data At IAS 2025, Including Monthly MK-8527 and Once-Weekly ISL/ULO Regimens

In a recent interview with CNBC, CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) CEO Michael Intrator acknowledged Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) as a strong rival in the artificial intelligence infrastructure sector.
What Happened: Intrator, in a conversation with CNBC&#8217;s Jim Cramer on Monday, emphasized the unique selling point of CoreWeave, differentiating it from Oracle. &#8220;Oracle has its own set of products that they&#8217;re offering, and they are a formidable competitor,&#8221; Intrator said, as reported by <a href="https://www.cnbc.com/2025/07/07/coreweave-ceo-calls-oracle-a-formidable-competitor-.html">CNBC</a>.
The CEO highlighted CoreWeave&#8217;s custom-built software stack, which he believes will set the company apart in the long run.  He stated, &#8220;From our position, we really believe that over time, what&#8217;s going to differentiate us from anyone else is the … software stack that drives the performance that we&#8217;re able to achieve on our infrastructure.&#8221;
Intrator added that CoreWeave&#8217;s software stack was developed from scratch, with optimization as the guiding principle. The company has deliberately avoided integrating any &#8220;legacy technology&#8221; or &#8220;history of success or failure.&#8221;
SEE ALSO: <a href="https://benzinga.com/news/legal/25/07/46289887/no-fast-lane-for-the-rich-lawyers-say-trumps-5-million-gold-card-visa-cant-fly-without-new-law" target="_blank" rel="noreferrer noopener">No Fast Lane For The Rich? Lawyers Say Trump&#8217;s $5 Million &#8216;Gold Card&#8217; Visa Can&#8217;t Fly Without New Law &#8211; Benzinga</a>
Why It Matters: On Monday, CoreWeave announced its decision to acquire Bitcoin miner, Core Scientific, in a $9 Billion <a href="https://www.benzinga.com/markets/tech/25/07/46284752/coreweave-just-valued-core-scientific-like-its-2021-again">all-stock deal</a>. The news led to a nearly 21% plunge in Core Scientific&#8217;s shares, even as the market remained unimpressed by CoreWeave&#8217;s move. However, this strategic acquisition was seen as a move that &#8220;makes strategic sense&#8221; <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46146598/core-scientifics-acquisition-by-coreweave-makes-strategic-sense-analysts-say">by analysts</a> earlier.
As CoreWeave continues to strengthen its position in the AI infrastructure space, the recognition of Oracle as a formidable competitor underscores the competitive landscape of this rapidly evolving sector. "The market's going to take some time to understand the extent of our business and the differentiation that's associated with how we go about running the software that drives the infrastructure," stated Intrator.
Notably, Jim Cramer had earlier called CoreWeave a &#8216;meme stock&#8217; on X after it surged more than 200% in a month, however, on Monday he stated, &#8220;Coreweave is truly something&#8230; Very positive.&#8221;
On a year-to-date basis, CoreWeave stock surged 299.25%.
Benzinga's Edge Rankings place CoreWeave in the 92nd percentile for momentum and the 16th percentile for value, reflecting mixed performance. Check the detailed report <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a>. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal">CoreWeave, Core Scientific Shares Move Lower On $9 Billion All-Stock Deal</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://x.com/jimcramer/status/1942324398666703341"></a>

CRWV

ORCL

CoreWeave CEO Bets On 'Custom-Built Software Stack' To Outpace Rivals— But Calls Oracle A 'Formidable Competitor'

TopBuild Corp. (NYSE:<a href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>), a leading installer and specialty distributor of insulation and related building material products to the construction industry in the United States and Canada, announced that it has entered into an agreement to acquire Progressive Roofing, a portfolio company of Bow River Capital, for $810 million in cash. This represents approximately 9.1x Progressive's earnings before interest, taxes, depreciation and amortization (EBITDA) for the trailing twelve months ended March 31, 2025, and a multiple of 8.6x EBITDA post-synergies, considering $5M in synergies. The transaction is expected to be immediately accretive to adjusted earnings per share.
Founded in 1978, Progressive Roofing is a leader in commercial roofing installation services in the United States, with a comprehensive offering that includes re-roofing, recurring maintenance services, and new construction. The company serves attractive commercial verticals, including education, technology, industrial, healthcare and government. Progressive generated $438 million in revenue and $89 million in EBITDA for the trailing 12 months ended March 31, 2025. Approximately 70% of the company's revenue is related to non-discretionary re-roofing and maintenance, while approximately 30% is from new construction. Based in Phoenix, Progressive employs more than 1,700 people across 12 branches.

TopBuild Buys Progressive Roofing for $810M to Boost Commercial Construction Reach

BlackRock is recalibrating its investment strategy, moving away from traditional macro anchors towards &#8220;mega forces&#8221; like artificial intelligence, which they believe will be &#8220;durable drivers of returns&#8221; in both the near and long term.
What Happened: This shift is detailed in their latest commentary, which emphasizes a more tactical approach to investing in a world where long-term macro stability is diminishing.
The firm notes that while &#8220;long-term macro anchors markets have relied on for decades, like stable inflation and fiscal discipline, have weakened,&#8221; this doesn&#8217;t necessitate a reduction in risk-taking.
Instead, mega forces or AI-related investments offer a &#8220;new anchor for returns.&#8221;
<a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus">BlackRock</a> also highlights the role of &#8220;immutable economic laws&#8221; in limiting the pace of global change, such as the inability to rewire supply chains overnight and the reliance of U.S. debt sustainability on foreign funding.
This perspective keeps BlackRock &#8220;risk on and overweight U.S. equities.&#8221;
Despite recent U.S. stock gains driven by the AI theme and a backdrop of persistent sticky inflation, the firm sees &#8220;scope for overall corporate earnings to stay solid even if U.S. growth is dented by tariff-induced disruptions and corporate caution.&#8221;
See Also: <a href="https://www.benzinga.com/markets/hedge-funds/25/07/46290114/bill-ackman-bets-over-60-of-pershing-squares-portfolio-in-these-4-stocks-uber-hhh-and-more">Bill Ackman Bets Over 60% Of Pershing Square&#8217;s Portfolio In These 4 Stocks: UBER, HHH And More</a>
Why It Matters: BlackRock anticipates that sticky inflation will prevent the Federal Reserve from significant rate cuts, and high fiscal deficits in the U.S. may prompt investors to seek a greater term premium on long-term debt.
The firm stresses that in this volatile environment, &#8220;set-and-forget portfolios no longer serve investors well,&#8221; advocating for active management across asset classes.
&#8220;Greater dispersion in market and security returns means more opportunity to capture alpha,&#8221; they conclude, reinforcing their belief that mega forces or AI investments will be pivotal in driving future returns.
Here are a few AI-linked exchange-traded funds that investors could consider amid ongoing optimism about the sector.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>iShares US Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>)</td>
<td>9.19%</td>
<td>11.00%</td>
</tr>
<tr>
<td>Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>)</td>
<td>7.44%</td>
<td>11.23%</td>
</tr>
<tr>
<td>First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>)</td>
<td>10.49%</td>
<td>28.91%</td>
</tr>
<tr>
<td>iShares Expanded Tech Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGM#NYSE">IGM</a>)</td>
<td>10.06%</td>
<td>15.00%</td>
</tr>
<tr>
<td>iShares Global Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXN#NYSE">IXN</a>)</td>
<td>9.53%</td>
<td>6.96%</td>
</tr>
<tr>
<td>Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>)</td>
<td>12.05%</td>
<td>42.81%</td>
</tr>
<tr>
<td>Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>)</td>
<td>1.66%</td>
<td>12.74%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Tuesday. The SPY was up 0.11% at $621.36, while the QQQ advanced 0.26% to $553.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors" target="_blank" rel="noreferrer noopener">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here's What It Means For Investors</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image via Shutterstock

First Trust Dow Jones Internet Index Fund

FTEC

iShares Trust S&P Global Information Technology Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

MAGS

QTUM

BlackRock Shifts Gears, Declares AI The New 'Anchor For Returns' As Inflation Stays Sticky

Samsung Electronics Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) on Tuesday announced plans to <a target="_blank" href="https://news.samsung.com/us/samsung-electronics-acquires-xealth-bridging-gap-between-wellness-medical-care/" rel="noreferrer noopener">acquire</a> Xealth, a digital health platform that integrates various tools into provider systems. This move advances Samsung&#8217;s strategy to build a more connected healthcare ecosystem. Deal terms were not disclosed.
The South Korean tech giant aims to link patient-generated wellness data from devices like smartwatches and the upcoming Galaxy Ring with clinical decision-making systems. The goal is to offer a more holistic, personalized approach to care.
Xealth, spun out of the Providence Health System, currently works with more than 500 hospitals in the U.S. and over 70 digital health partners. The platform helps health systems manage digital tools from a single interface, enabling real-time monitoring and patient engagement.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46288786/us-export-bans-and-nvidia-supply-issues-crush-samsung-chip-profits-hopes-rest-on-ultra-thin-foldables-smartwatches-and-possible-xr-debut-at-galaxy-unpacked-event" rel="noreferrer noopener">US Export Bans And Nvidia Supply Issues Crush Samsung Chip Profits — Hopes Rest On Ultra-Thin Foldables, Smartwatches And Possible XR Debut At Galaxy Unpacked Event</a>
&#8220;Samsung aims to improve the health of everyone through our extensive platform combining Samsung&#8217;s innovative technologies and open collaboration with industry leaders,&#8221; said TM Roh, president and acting head of Samsung&#8217;s Device eXperience Division.
Mike McSherry, CEO of Xealth, said combining clinical data with wearable insights can deliver new data analysis opportunities and enhance provider workflows.
The acquisition is expected to close in 2025, pending regulatory approvals. It marks a significant step in Samsung&#8217;s transition from consumer electronics to digital health infrastructure, reinforcing its care-at-home strategy.
Related ETFs include iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>) and Global X HealthTech ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAL#NASDAQ">HEAL</a>).
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale" target="_blank" rel="noreferrer noopener">OpenAI Sticks With Nvidia: ChatGPT Maker Says No Plans To Use Google&#8217;s AI Chips At Scale</a></li>
</ul>
Photo by Sybillla via Shutterstock

Tech

HEAL

iShares Dow Jones US Medical Devices Index Fund

SSNLF

Samsung's Xealth Acquisition Connects Patient Data To Clinical Care

Buc-ee's is accelerating its march beyond Texas, eyeing more than a dozen new mega travel centers that could push the cult-favorite chain past 70 stores in 17 states by 2027.
What Happened: The privately held company already operates 54 outlets across nine states, recently adding Mississippi, Virginia and a third Georgia location to its map, according to a syndicated release <a href="https://thehill.com/homenews/nexstar_media_wire/5386795-buc-ees-is-expanding-where-future-travel-centers-are-set-to-open/">shared</a> with The Hill.
The expansion wave began June 9 with Mississippi's <a href="https://www.wlox.com/2025/06/09/mississippis-first-buc-ees-opens-business-harrison-county/">first</a> Buc-ee's near Gulfport and continued June 30 when a 74,000-square-foot site opened near Harrisonburg, Va., becoming the chain's <a href="https://www.washingtonpost.com/dc-md-va/2025/07/04/bucees-virginia-store-review/">northernmost</a> store. One day later Buc-ee's cut the ribbon on Georgia's <a href="https://www.fox5atlanta.com/news/new-buc-ees-opens-near-brunswick-largest-location-georgia">largest</a> unit in Brunswick.
Construction crews are busy far afield. In Benton, Ark., Gov. Sarah Huckabee Sanders (R) <a href="https://x.com/SarahHuckabee/status/1913028666394546590">hailed</a> the company's "largest groundbreaking ever" for a 75,000-square-foot travel center due in 2026. West Memphis is set to follow. 
Ohio's first store is rising in Huber Heights after utility delays pushed the debut to spring 2026. Murfreesboro, Tennessee, targets a 2026 opening, while a separate Gallaway site could land in 2027.
See also: <a href="https://www.benzinga.com/markets/hedge-funds/25/07/46290114/bill-ackman-bets-over-60-of-pershing-squares-portfolio-in-these-4-stocks-uber-hhh-and-more">Bill Ackman Bets Over 60% Of Pershing Square&#8217;s Portfolio In These 4 Stocks: UBER, HHH And More</a>
Why It Matters: The chain is also planting its beaver flag westward. Goodyear will host Arizona's inaugural Buc-ee's, now under construction and Oak Creek has cleared the last local hurdle for Wisconsin's first store. 
In Louisiana, travel centers in Ruston and Lafayette are penciled in for mid-2026 after roadwork delays. North Carolina's debut in Mebane and a massive Monroe County, Georgia, project round out the announced pipeline.
Some deals still face potholes. A $60 million interchange upgrade has stalled plans in Anderson County, South Carolina. However, if every shovel-ready site opens on schedule, the chain known for spotless restrooms, 120-pump forecourts and its Beaver Nuggets snack will cement its status as America's fastest-growing roadside oasis.
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale">OpenAI Sticks With Nvidia: ChatGPT Maker Says No Plans To Use Google&#8217;s AI Chips At Scale</a></li>
</ul>
Image Courtesy: Joseph Hendrickson / Shutterstock.com

Retail Sales

Buc-ee's Plans Dozen-Plus New Mega Stores, Aiming For 70 Locations Across 17 States By 2027 — Here's Where Its Expanding To

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">KinderCare Learning Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>)</h3>
<ul class="wp-block-list">
<li>On June 11, Goldman Sachs analyst George Tong maintained KinderCare Learning with a Buy and lowered the price target from $26 to $23. The company's stock fell around 16% over the past month and has a 52-week low of $9.17.</li>
<li>RSI Value: 26.8</li>
<li>KLC Price Action: Shares of KinderCare Learning fell 7% to close at $9.25 on Monday.</li>
<li>Edge Stock Ratings: Value at 29.38.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/KLC"><img loading="lazy" decoding="async" width="428" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062756/image-70.png" alt="" class="wp-image-976256" style="width:268px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062756/image-70.png 428w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062756/image-70-300x124.png 300w" sizes="(max-width: 428px) 100vw, 428px" /></a></figure>
<h3 class="wp-block-heading">Bright Horizons Family Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On June 23, Jefferies analyst Hamzah Mazari downgraded Bright Horizons Family from Buy to Hold and lowered the price target from $146 to $135. The company's stock fell around 5% over the past five days and<a href="https://www.benzinga.com/quote/BFAM"> has a 52-week low</a> of $103.75.</li>
<li>RSI Value: 28.3</li>
<li>BFAM Price Action: Shares of Bright Horizons Family Solutions fell 2.8% to close at $117.24 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708">BFAM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708"><img loading="lazy" decoding="async" width="915" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062903/image-71.png" alt="" class="wp-image-976259" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062903/image-71.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062903/image-71-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062903/image-71-768x693.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Gaotu Techedu Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>)</h3>
<ul class="wp-block-list">
<li>On May 15, Gaotu Techedu reported a year-over-year increase in first-quarter sales results. Larry Xiangdong Chen, the Company&#8217;s founder, Chairman and CEO, commented, &#8220;In the first quarter of 2025, we delivered results that surpassed expectations across revenue, profit, user growth, and organizational efficiency." The company's stock fell around 14% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/GOTU">low of $1.87.</a></li>
<li>RSI Value: 29.9</li>
<li>GOTU Ltd Price Action: Shares of Gaotu Techedu fell 2.3% to close at $3.45 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708">GOTU shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708"><img loading="lazy" decoding="async" width="898" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062955/image-72.png" alt="" class="wp-image-976262" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062955/image-72.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062955/image-72-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08062955/image-72-768x707.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

BFAM

GSX Techedu Inc. American Depositary Shares

GOTU

Top 3 Consumer Stocks Which Could Rescue Your Portfolio In July

WeightWatchers Completes Strategic Reorganization, Relists on Nasdaq, Revamps Leadership Team, and Launches Menopause Health Initiative

WeightWatchers Names Jon Volkmann Chief Operating Officer To Oversee Clinical, Field, And Community Operations Amid Strategic Expansion

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay.
IRVING, Texas, July 8, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4463891-1&amp;h=50456937&amp;u=https%3A%2F%2Fwww.carislifesciences.com%2F&amp;a=Caris+Life+Sciences">Caris Life Sciences</a>&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAI#NASDAQ">CAI</a>), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in&nbsp;Scientific Reports, a Nature journal,&nbsp;demonstrating the accuracy and clinical utility of the Caris Assure&#xAE;&nbsp;blood-based biopsy assay across the cancer continuum.
The Caris Assure&#xAE;&nbsp;platform is a breakthrough single assay that combines comprehensive, highly sophisticated molecular profiling of all 23,000+ genes across DNA and RNA in plasma, setting a new blood-based testing standard and revolutionizing management of the cancer care journey. Additionally, Caris sequences DNA in the "buffy coat," the layer of centrifuged blood between the red blood cells and plasma, which contains white blood cells and platelets. Caris Assure combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) with advanced machine learning on a single platform.&nbsp;Caris Assure&#xAE; is currently used for therapy selection and is capable of enabling accurate early detection and highly sensitive disease monitoring.
The Caris Assure&#xAE;&nbsp;liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI (ABCDai), was trained on over&nbsp;376,000 whole exome and whole transcriptome tissue profiles&nbsp;and&nbsp;over 7,000 matched blood and tissue samples. In addition to therapy selection, the study validates the performance of Caris Assure&#xAE;&nbsp;in:
<ul>
<li>Multi-Cancer Early Detection (MCED):&nbsp;Achieved sensitivities of&nbsp;83.1% to 95.7%&nbsp;across cancer stages I–IV at&nbsp;99.6% specificity.</li>
<li>Diagnostic Pathway Predictor:&nbsp;Accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model.</li>
<li>MRD and Recurrence Monitoring:&nbsp;Demonstrated significant predictive power for recurrence, with hazard ratios of&nbsp;33.4 (p &lt; 0.005)&nbsp;for MRD and&nbsp;4.39 (p = 0.008)&nbsp;for therapeutic monitoring.</li>
</ul>
Caris Assure&#xAE;&nbsp;does not require a prior tissue biopsy. Instead, its AI model identifies tumor-derived signals based on patterns learned from hundreds of thousands of tumors. This enables a&nbsp;tissue-agnostic, highly sensitive approach to cancer detection and monitoring.
While Caris Assure&#xAE;&nbsp;is currently commercially available for therapy selection in advanced cancers, this study lays the groundwork for expanding into early detection, MRD and therapeutic monitoring. Caris is actively pursuing reimbursement and regulatory pathways to bring these applications to market.

Caris Life Sciences Announces New Study Demonstrating Accuracy And Clinical Utility Of Caris Assure Blood-Based Biopsy Assay Across Cancer Continuum

Air Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AL#NYSE">AL</a>) announced an update on aircraft investments, sales, and other activities occurring in the second quarter of 2025.
As of June 30, 2025, AL's fleet was comprised of 495 owned aircraft and 53 managed aircraft, with 241 new aircraft on order from Airbus and Boeing set to deliver through 2031.
Aircraft Investments
<ul>
<li>Delivered 12 new aircraft from AL's orderbook including six Airbus A220s, one A321neo, two Boeing 737-8s, one Boeing 787-9, and two Boeing 787-10s.</li>
<li>Aircraft investments totaled approximately $890 million, with the majority occurring in the second half of the quarter.</li>
</ul>
Sales
<ul>
<li>Sold 4 aircraft to third-party buyers.</li>
<li>Aircraft sales proceeds for the quarter totaled approximately $126 million.</li>
</ul>
Russia Fleet Insurance Settlements
<ul>
<li>Recognized a net benefit of $344 million from the settlement with certain insurers of insurance claims related to our former Russian fleet.</li>
</ul>

Air Lease Invests $890M in New Jets, Nets $344M From Russia Insurance Settlement, Adds 12 Aircraft as Global Fleet Expands

ISOU

IsoEnergy And Purepoint Advance Uranium Discovery With Promising Intercepts And Follow-Up Drilling At Q48

GPUS

Hyperscale Data Reports $11.2M YTD Bitcoin Mining Revenue, Including $1.5M In June 2025; 18,200 Antminers Now Operational Across Sites

BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>), a pioneer in advanced dehydration technology and clean-label snacks, is proud to announce a major national expansion with the nation's largest retailer. Following the exceptional performance of its innovative Brussels Sprout Crisps, BranchOut has been awarded a nationwide rollout of the product into 3,945 stores, up from the 2024 launch in approximately half of their stores.
This milestone underscores the strength of BranchOut's ability to deliver true innovation and the rising demand for its unique snack offerings. The Brussels Sprout Crisps, the first of their kind in the market, launched last year to overwhelming consumer response. Their strong velocity and category-defining nature helped solidify their place as a standout new item.
In addition to the expanded distribution of the Brussels Sprouts, BranchOut will also debut its newest innovation: Sweet Potato Sticks Topped with Cinnamon, launching into 1,952 stores, representing approximately 50% of the retailer's footprint. These new snacks offer a lightly sweet, crunchy experience and are crafted using BranchOut's proprietary GentleDry&#x2122; technology to preserve the vibrant color, flavor, and nutrition of the sweet potatoes.

BranchOut Food Expands to Nearly 4,000 Stores as Brussels Sprout Crisps Go National

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Comments

Trump Media & Tech Gr

Vendite allo scoperto

Trump Media & Tech Gr (NASDAQ:DJTWW) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO